Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Annovis (anvs) ad study to continue as planned, shares rise
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase ...
October 13, 2023, 2:16 pm
Foxtons hopes pinned on rentals as high mortgages yet to bite
Estate agents Foxtons (LSE:FOXT) Group PLC will delve into the state of the UK's housing market in its upcoming third-quarter results on Thursday, Oct...
October 13, 2023, 6:46 am
Hays comes out in front in lukewarm recruitment earnings season
This week saw trading updates from three prominent London-listed recruitment agencies, with Robert Walters PLC (LSE:RWA)'s ...
October 12, 2023, 7:13 am
Oxford instruments slips on lower-end profit expectations
Shares in Oxford Instruments PLC (AIM:OXIG) slipped by 5% on Thursday after the technology systems provider warned of muted trading for the remainder ...
October 12, 2023, 4:48 am
Why dialysis stocks plunged today
Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on ...
October 11, 2023, 12:51 pm
Novo nordisk (nvo) up on positive kidney outcomes study update
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis result...
October 11, 2023, 10:32 am
E2open parent holdings, inc. (etwo) q2 2024 earnings call transcript
E2open Parent Holdings, Inc. (NYSE:ETWO ) Q2 2024 Earnings Conference Call October 10, 2023 5:00 PM ET Company Participants Dusty Buell - Head of IR A...
October 10, 2023, 8:52 pm
Novo nordisk to stop ozempic trial to treat renal impairment early
Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal ...
October 10, 2023, 5:30 pm
Bp says remains committed to financial, climate ambitions
BP said on Tuesday it remained committed to its financial and carbon reduction ambitions, at a start of an investor day in Denver led by ...
October 10, 2023, 10:38 am
U stock alert: unity ceo john riccitiello is stepping down
Unity Software (NYSE: U ) stock is climbing about 4% after the company announced that its CEO, John Riccitiello, had resigned and would be replaced on...
October 10, 2023, 10:08 am